Tobias Suter

Title: Innovations by Tobias Suter in Antigen Binding Molecules

Introduction

Tobias Suter is a notable inventor based in Windisch, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of antigen binding molecules. With a total of four patents to his name, Suter's work focuses on enhancing therapeutic properties of antibodies.

Latest Patents

Suter's latest patents include innovations related to polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function. These inventions involve nucleic acids that encode recombinant monoclonal antibodies, including chimeric, primatized, or humanized antibodies specific for human CD20. The patents also cover isolated polynucleotides and methods for producing these antigen binding molecules, which have improved therapeutic properties due to modified glycosylation.

Career Highlights

Tobias Suter is currently associated with Roche Glycart AG, a company known for its advancements in antibody engineering. His work at Roche has allowed him to focus on innovative solutions in the treatment of diseases through the development of effective antibody therapies.

Collaborations

Suter has collaborated with notable colleagues such as Pablo Umaña and Peter Brünker. These collaborations have contributed to the advancement of research in the field of monoclonal antibodies.

Conclusion

Tobias Suter's contributions to the field of biotechnology, particularly in the development of antigen binding molecules, highlight his innovative spirit and dedication to improving therapeutic options. His work continues to influence the landscape of antibody therapies.